As the MRI is highly sensitive for monitoring disease activity, it is regarded as surrogate. In particular, the MRI is meaningful when the size or the number of lesions increases, or gadolinium enhancement or atrophy is found, and may require a change in treatment, even if the patient is asymptomatic. Vice versa, if no gadolinium enhancement or atrophy could be found, or the size and numbers of lesions decrease or even disappear, it might suggest that the disease activity is below the detection limit or that disease activity spontaneously passes by and that repair mechanisms fully work or that that the therapy is effective. Probably, the biggest advantage of the MRI is that the entire brain and spinal cord and their changes can be displayed in vivo, thus it allows neurologists to look inside their patients.
In contrast to MRI, the possible uses of OCT are more limited as it allows, from a strict scientific point of view, only a scan of the retina and measurement of its total thickness/volume or of individual retinal layers.
Due to technical reasons, it is impossible to detect the brain or spinal cord volume or any other central nervous system (CNS) parameter of interest below the actual scanning resolution and outside of the scan depth of an OCT device. Associations between OCT readings and brain and spinal cord measurements may thus only indicate association, but no causality, and might be only stochastic or spurious until proven otherwise. [4] [5] [6] Nevertheless, the most crucial question remains whether the proposed subtle retinal thickness changes can be detected within confounding and rather gross damages following episodes of optic neuritis? Furthermore, it remains unanswered whether small and clinically silent focal demyelination in the optic nerves, which are found in brain autopsies of nearly all MS patients, correlate as well to various other parameters such as brain and spinal cord atrophy and the Expanded Disability Status Scale (EDSS)? 2, 7 Indeed, this would provide a more plausible explanation for the correlation between retinal thickness and disability than the proclaimed hypothesized transsynaptical retrograde neurodegeneration. 8 And, it might explain the clinico-radiologico-ophthalmological paradox (CROP) in MS, which we have described and proposed. 6 As every MS patient seems to follow his own individual course with an individual set of paraclinical parameters, we concluded that the wellknown "clinico-radiological paradox" or "radiological isolated syndrome" also applies to the OCT.
The biggest advantage of OCT over MRI is that the OCT is cheap and readily available and flexible in use for clinical trials. But one of the main reasons for suggesting OCT as new surrogate for MS monitoring is the hypothesis that "retinal thinning" reflects an underlying, steadily ongoing, diffuse and progressive neurodegenerative process in the CNS of all MS patients. Note, this hypothesis is in particular based on reduction of the retinal nerve fiber layer in very early stages of relapsing-remitting MS and clinically isolated syndrome patients, which has been described recently. 9 This, in turn, would imply that the retina and the brain and spinal cord are mutually inter-linked by the same so far undefined pathological mechanism and, most importantly, that their changes correlate simultaneously and strictly. As a consequence, the "retinal thinning" should also correlate to the brain and spinal cord atrophy parameters seen on MRI of MS patients or at least, to the disability of MS patients, which is usually measured by the EDSS. But a strict correlation and "retinal thinning" have yet not been demonstrated. 4, 6 Anyway, the most crucial point is that the often used term "retinal thinning" should be avoided and replaced, for instance, by the neutral terms "retinal nerve fiber layer reduction" or "thickness." The semantic meaning of terms influences our scientific thinking, expectation and, most importantly, also our scientific discernment and judgment and thus it may explain the hype of OCT. Visual evoked potential (VEP) has been found to be equal or even superior to OCT, 10 but who would consider replacing it with a cranial MRI?
In conclusion, the OCT cannot be a substitute for an MRI as it does not allow an interrogation of the brain, spine, or optic nerves and as its associations are modest and may not reflect pathologic relationships.
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The author(s) received no financial support for the research, authorship, and/or publication of this article. A basic presumption about a useful tool for monitoring disease is not only that the metric measures some salient aspect of disease pathobiology but that responding to that metric would yield some tangible clinical benefit for patients. Since its introduction to the field 19 years ago, optical coherence tomography (OCT) has been suggested to hold promise as a biomarker for tracking disease progression in multiple sclerosis (MS). 1 In this issue of Multiple Sclerosis, Sotirchos and Saidha take up the contentious position that OCT has now reached the mature state that it may be more valuable than magnetic resonance imaging (MRI) in monitoring MS. However, ultimately, the authors hedge in claiming that OCT's singular advantage over MRI is its cost and ready availability, but yield that the technique is only complementary to MRI. 2 MRI has proven itself extraordinarily useful at aiding in the diagnosis of MS. So much so that MRI has assumed an increasingly central role in unfolding iterations of the diagnostic criteria used to confirm an MS diagnosis. 3 Furthermore, gadolinium-enhancing lesions and new T2 lesions on MRI have proven to be meaningfully associated with relapses and short-term progression of disability in MS. These measurements have become standardized as outcome measures in phase-II clinical trials assessing immunomodulatory disease-modifying therapies. Mounting evidence has also suggested that use of these immunomodulatory agents has been associated with a reduction in long-term disability in MS and a delay in reaching disability milestones and even mortality in MS. 4, 5 This would naturally lead one to conclude that MRI is a useful tool for monitoring progression in MS-and as claimed by Djamshidian and Seberic 6 that it is a better tool than OCT because it measures damage to the whole neuroaxis rather than just the retina. However, the question tackled by the two opposing sides was loaded from the start-it is prefaced on the assumption that MRI (as it is currently utilized in routine clinical management of MS) is useful for tracking the disease. Still more than 30 years since its introduction, it is far from clear that MRI is truly useful for monitoring disease progression in MS. In fact, longterm data suggest that MRI fails as a monitoring tool-as changes in therapy brought about by MRI evidence of disease do not appear to result in benefits for patients when viewed over a longer time frame. 4 Similarly, although OCT metrics correlate with disease progression over time, it has not been shown that changes in existing treatments brought about by responding to changes on OCT yields any benefit to patients. For now, the evidence would seem to suggest that standard MRI sequences fail as monitoring tools and that OCT has not been adequately assessed. Newer, refined, or focused sequences on MRI may prove to be better and more useful 7 -although focusing on a single area of the central nervous system (CNS) such as the thalamus or spinal cord may suffer the same limitations attributed to OCT.
